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ABSTRACT
Delta-like 4 (DLL4) and Jagged1 (JAG1) are two key Notch ligands implicated in 
tumour angiogenesis. They were shown to have opposite effects on mouse retinal and 
adult regenerative angiogenesis. In tumours, both ligands are upregulated but their 
relative effects and interactions in tumour biology, particularly in tumour response 
to therapeutic intervention are unclear. Here we demonstrate that DLL4 and JAG1 
displayed equal potency in stimulating Notch target genes in HMEC-1 endothelial 
cells but had opposing effects on sprouting angiogenesis in vitro. Mouse DLL4 or 
JAG1 expressed in glioblastoma cells decreased tumour cell proliferation in vitro 
but promoted tumour growth in vivo. mDLL4-expressing tumours showed fewer but 
larger vessels whereas mJAG1-tumours produced more vessels. In both tumour types 
pericyte coverage was decreased but the vessels were more perfused. Both ligands 
increased tumour resistance towards anti-VEGF therapy but the resistance was higher 
in mDLL4-tumours versus mJAG1-tumours. However, their sensitivity to the therapy 
was restored by blocking Notch signalling with dibenzazepine. Importantly, anti-
DLL4 antibody blocked the effect of JAG1 on tumour growth and increased vessel 
branching in vivo. The mechanism behind the differential responsiveness was due to 
a positive feedback loop for DLL4-Notch signalling, rendering DLL4 more dominant in 
activating Notch signalling in the tumour microenvironment. We concluded that DLL4 
and JAG1 promote tumour growth by modulating tumour angiogenesis via different 
mechanisms. JAG1 is not antagonistic but utilises DLL4 in tumour angiogenesis. The 
results suggest that anti-JAG1 therapy should be explored in conjunction with anti-
DLL4 treatment in developing anti-Notch therapies in clinics.
INTRODUCTION
Angiogenesis is a multifaceted process involving 
matrix degradation, endothelial cell (EC) proliferation, 
migration, sprouting and recruitment of mural cells. 
Tumour angiogenesis is regulated by many angiogenic 
molecules including VEGF, which are produced by tumour 
or stromal cells within the tumour microenvironment 
[1]. Notch signalling can be activated in ECs following 
contact between stromal cells, ECs and tumour cells 
[2]. Both Delta-like 4 (DLL4) and Jagged1 (JAG1) 
ligands are implicated in tumour angiogenesis. DLL4 
is predominantly expressed in the ECs of tumour blood 
vessels [3-10] but also in a small proportion of tumour 
cells [5, 7]; whereas JAG1, although also expressed in 
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ECs [11, 12], is more highly expressed in tumour cells 
[13-16] and mural cells [17, 18]. These ligands have 
opposing effects on vessel formation. DLL4 has been 
shown to inhibit sprouting resulting in fewer but better 
perfused blood vessels, which promoted tumour growth 
[6-8, 19, 20]. JAG1 on the other hand can signal to both 
tumour cells and ECs [11, 12, 21] to promote angiogenesis 
and tumour growth via the MAPK pathway [16, 22]. 
Molecularly, DLL4 binds to the region of EGF-like repeats 
1-13 on Notch1 while JAG1 binds to the repeats of 10-24 
as the fragments containing such repeats effectively block 
the function of DLL4 and JAG1 respectively [23]. The 
2.3-angstrom resolution crystal structure of the interacting 
regions of the Notch1-DLL4 complex further reveals 
a two-site, antiparallel binding orientation assisted by 
Notch1 O-linked glycosylation [24]. 
Interestingly, in a retina model the expression of 
DLL4 was shown to fluctuate dynamically in individual 
ECs within sprouting vessels [25] while JAG1 antagonised 
DLL4-Notch signalling during sprouting angiogenesis, 
thereby enhancing retina angiogenesis [26]. In the JAG1-
engineered mice, EC-specific JAG1 deletion resulted in 
upregulation of DLL4-Notch signalling in the vessels 
shown by increasing HES1, HEY1 and DLL4 expression 
throughout ECs, reduced endothelial proliferation and 
decreased vessel branching [26]. Endothelial JAG1 also 
antagonized DLL4 regulation of endothelial branching 
and increased vascular maturation downstream of DLL4-
Notch1 in a skin wound healing model [27] as well as 
promoted tumour growth through pro-angiogenic and 
angiocrine functions [28]. 
Many studies have focused on the effects of 
endothelial DLL4 or JAG1 on tumour growth and 
vascularisation. However, whether there is any function 
interaction between DLL4 and JAG and how such an 
interaction would affect tumour angiogenesis and tumour 
growth and progression are unknown. Prospectively, 
it would be important for targeted therapy if they were 
antagonistic in tumour. Therefore, we investigated different 
effects of DLL4 and JAG1 on in vitro angiogenesis, on 
xenograft tumour growth and vasculature, and on tumour 
response to anti-VEGF therapy.
RESULTS
DLL4 and JAG1 had opposite effects on sprouting 
angiogenesis in vitro by activating notch signalling
Both rhDLL4 and rrJAG1, when coated on plates 
(18nM, chosen from dose response curves to induce 
target genes maximally, data not shown), were capable of 
upregulating the expression of DLL4, JAG1, HEY1, and 
HEY2 in HMEC-1 at mRNA levels with an equal potency 
(Figure 1A). However, rhDLL4 upregulated DLL4, JAG1, 
HEY1 and HEY2 more strongly in HUVECs than rrJAG1 
did (Supplementary Figure S1A). 
DLL4 and JAG1 were then upregulated by 
retroviral transductions (Supplementary Figure S1B) and 
downregulated by knockdown of endogenous hDLL4 and 
hJAG1 in HMEC-1 respectively (Supplementary Figure 
S1C and S1D). When stably expressed in HMEC-1, 
mDLL4 increased the expression of endogenous hDLL4 
approximately 8.2-fold whereas mJAG1 only increased 
hDLL4 expression about 2.1-fold (Figure 1B). Induction 
of HEY1 and HEY2 was also higher in mDLL4-expressing 
cells compared to mJAG1-expressing cells. However, both 
mDLL4 and mJAG1 equally upregulated the expression of 
endogenous JAG1 (2.7-fold versus 2.8-fold) (Figure 1B). 
FACS analysis for measuring the expression of 
hDLL4 or hJAG1 at protein levels in parental HMEC-
1 cells that were sorted from co-culture of ligand-
overexpressing HMEC-1 cells by mixing an equal amount 
of parental cells showed that mDLL4 stimulated the 
expression of endogenous hDLL4 significant stronger than 
mJAG1 did, whereas both mDLL4 and mJAG1 equally 
induced the expression of endogenous hJAG1 compared 
to the EV control (Figure 1C), consistent with the mRNA 
results. 
The role of these ligands in endothelial sprouting 
was investigated using hanging drop assays. mDLL4 
decreased sprouting while mJAG1 promoted sprouting 
of HMEC-1 (Figure 1D). Blocking Notch signalling 
with DBZ increased sprouting in all EV-, mDLL4- and 
mJAG1-spheroids. Knockdown of endogenous hDLL4 
(Figure 1E) or hJAG1 (Figure 1F) by specific siRNAs 
showed opposite effects on sprouting angiogenesis. 
siDLL4 significantly increased sprouting (Figure 1E) 
while siJAG1 decreased sprouting (Figure 1F). Treatment 
with DBZ increased sprouting in controls and abolished 
the siJAG1 suppressive effect by increasing sprouting. 
DLL4 and JAG1 reduced cell proliferation in 
vitro but promoted tumour growth in vivo through 
different vasculature phenotypes
mDLL4 or mJAG1, expressed in U87 cells as 
confirmed by Western blotting (Figure 2A), reduced cell 
proliferation in vitro (Figure 2B) but promoted tumour 
growth in vivo and decreased mouse survival (Figure 2C). 
Implantation of an equal amount of mDLL4- and mJAG1-
expressing tumour cells in mice produced similar results 
in terms of tumour growth and mouse survival to that of 
mDLL4- or mJAG1-expressing tumour (Figure 2C). DBZ 
did not seem to significantly affect xenograft growth of 
EV cells but abolished the promotion of tumour growth 
by either mDLL4 or mJAG1 (Figure 2D), suggesting 
that promotion of tumour growth by both ligands were 
mediated by activation of Notch signalling. 
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Immunofluorescent staining of tumour sections with 
anti-CD31 antibody showed that mDLL4 expressed in 
tumour cells reduced vessel density but increased vessel 
size compared to the EV control (Figure 2E), consistent 
with the result obtained from hDLL4 [6]. In stark contrast, 
mJAG1 expressed in tumour cells dramatically increased 
vessel density but not vessel size. DBZ treatment not 
only increased vessel density in all three types of tumours 
but also abolished the larger vessels in mDLL4-tumour, 
suggesting that the larger vessels induced by mDLL4 were 
promoted by mDLL4-Notch signalling. Vascular perfusion 
assays by a tail vein injection of tomato-lection into the 
Figure 1: DLL4 and JAG1 activated Notch signalling and affected sprouting angiogenesis in vitro. A. Expression profile 
of Notch target genes in HMEC-1 stimulated with rhDLL4 or rrJAG1 over a time course. QPCR was used to determine mRNA levels of 
DLL4, JAG1, HEY1 and HEY2. Fold changes were obtained by normalizing against the EV control.B. Expression profile of Notch target 
genes in HMEC-1 over-expressing mDLL4 or mJAG1 by retrovirus transductions. QPCR was used to determine mRNA levels of DLL4, 
JAG1, HEY1 and HEY2 (ANOVA with Bonferroni’s post-test). C. Expression of endogenous hDLL4 and hJAG1 proteins in parental 
HMEC-1 cells (GFP-negative) sorted from co-culture of EV-, mDLL4- or mJAG1-overexpressing HMEC-1 with an equal amount of 
parental HMEC-1 cells by FACS analysis (ANOVA with Bonferroni’s post-test). D. Effect of mDLL4 and mJAG1 expressed in HMEC-1 
cells on sprouting in HMEC-1 spheroids and treated with DBZ. Average lengths of three longest sprouts were calculated for statistical test 
(ANOVA with Bonferroni’s post-test). Graphs are means of 3 independent experiments. E. Effect of knockdown of DLL4 in HMEC-1 
cells by specific siDLL4 on sprouting in HMEC-1 spheroids. Average lengths of three longest sprouts were calculated for statistical test 
(ANOVA with Bonferroni’s post-test). Graphs are means of 3 independent experiments. F. Effect of knockdown of JAG1 in HMEC-1 cells 
by specific siJAG1 on sprouting in HMEC-1 spheroids. Average lengths of three longest sprouts were calculated for statistical test (ANOVA 
with Bonferroni’s post-test). Graphs are means of 3 independent experiments. *P<0.05, ** P<0.01.
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tumour and staining on tumour sections demonstrated that 
both mDLL4 and mJAG1 significantly increased vascular 
perfusion in mDLL4- and mJAG1-tumour compared to 
that of EV-tumour (Figure 2E and 2F). DBZ treatment did 
not significantly affect vascular perfusion in EV-tumour 
but abolished the promotion of vascular perfusion in either 
mDLL4- or mJAG1-tumour.
mDLL4 or mJAG1 expressed in other three tumour 
cell lines as confirmed by FACS analysis (Supplementary 
Figure S2A) significantly reduced in vitro growth of SAS 
cells but not PC3 and DU145 cells (Supplementary Figure 
S2B). However, there were no significant effects on either 
tumour growth or mouse survival for all these three tumour 
types compared to the relevant EV-control (Supplementary 
Figure S2C). Tumour vasculature evaluation revealed 
that mDLL4 significantly decreased vessel number but 
increased vessel size compared to the EV control while 
mJAG1 greatly increased vessel number but not vessel 
size in all these three tumour types (Supplementary Figure 
S2D).
DLL4 and JAG1 mediated tumour resistance to 
anti-VEGF therapy with bevacizumab
Bevacizumab treatment of EV-tumour significantly 
delayed tumour growth (Figure 3A) compared to vehicle 
control (EV:mAb versus EV:Control). mDLL4 expressed 
Figure 2: mDLL4 and mJAG1 reduced proliferation in vitro but promoted tumour growth of U87 cells in vivo via 
different vasculature. A. Upregulation of mDLL4 and mJAG1 in U87 cells by retrovirus transductions. Western blotting confirmed the 
expression of mDLL4 and mJAG1. GFP encoded by the retrovirus vector was served as an internal control for the transduction efficacy. 
β-actin was served as a protein loading control. B. In vitro cell proliferation assays of U87 cells over a time course. N = 4. Error bars 
represent SD. C. Tumour growth and mouse survival of U87-EV, U87-mDLL4, U87-mJAG1 and U87-mDLL4+U87-mJAG1 (50%/50%) 
in mice. Parametric generalized linear model with random effects was used for tumour growth test and Kaplan-Meier analysis for overall 
survival test. Each group consisted of 5 mice. D. Tumour growth of U87-EV, U87-mDLL4 and U87-mJAG1 in mice treated with DBZ 
(8.1µmol/kg body weight, ip every 3 days). Each group consisted of 5 mice. Parametric generalized linear model with random effects was 
used for statistical test. E. Tumour vascular phenotype and vascular perfusion results. Immunofluorescence double staining for vessels 
(CD31, green) and tomato-lectin (red). Magnification 200X. F. Quantification of vascular perfusion. Graphs are means of perfusion per 
vessel area in 5 tumours. ANOVA with Bonferroni’s post-test. *P<0.05, ** P<0.01, *** P<0.001.
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in U87 cells conferred tumours more resistance to anti-
VEGF therapy as shown by the shorter delay for 5 days 
(mDLL4:control versus mDLL4:mAb) compared to the 
14-day delay in EV-tumours (EV:control versus EV:mAb). 
Similarly, mJAG1 expressed in U87 also instigated 
tumour resistance to anti-VEGF therapy (Figure 3B) as 
reflected by the growth delay for 9 days (mJAG1:control 
versus mJAG1:mAb) compared to the 14-day delay in 
EV-tumours (EV:control versus EV:mAb). However, 
such resistance contributed by mJAG1 (5-day difference, 
Figure 3B) was significantly weaker than that contributed 
by mDLL4 (9-day difference, Figure 3A).
DBZ treatment did not significantly affect EV-
tumour growth compared to vehicle control (EV:DBZ 
versus EV:Control) but dramatically postponed xenograft 
growth of either mDLL4-tumour (mDLL4:DBZ 
versus mDLL4:Control, Figure 3A) or mJAG1-tumour 
(mJAG1:DBZ versus mJAG:Control, Figure 3B). 
Combined DBZ and bevacizumab treatment 
exhibited an additive inhibitory effect on the growth 
of mDLL4-tumours when compared to either DBZ 
(mDLL4:DBZ+mAb versus mDLL4:DBZ) or 
bevacizumab therapy (mDLL4:DBZ+mAb versus 
mDLL4:mAb) (Figure 3A) but such an effect was 
not clear for EV-tumours (EV:DBZ+mAb versus 
EV:mAb). Combined DBZ with bevacizumab treatment 
(mJAG1:DBZ+mAb) showed a synergistic inhibition 
effect on the growth of mJAG1-tumours compared to DBZ 
(mJAG1:DBZ) or bevacizumab (mJAG1:mAb) alone 
(Figure 3B). 
Therapeutic effects on tumour vasculature
Expression of mDLL4 decreased vessel number 
but increased vessel size, whereas expression of mJAG1 
increased vessel number but not vessel size when 
compared to EV control. Pericyte coverage, as detected 
by NG2 staining [29], decreased significantly in both 
mDLL4- and mJAG1-tumours when compared to that in 
EV-tumour (II-III versus I) (Figure 3C).
Bevacizumab reduced vessel density in EV-, 
mDLL4- and mJAG1-tumours (VII-IX versus I-III) but 
did not affect pericyte coverage in mDLL4- and mJAG1-
tumours (VIII-IX versus II-III).
DBZ treatment increased vessel numbers in EV 
and mDLL4 groups (IV-V versus I-II) but significantly 
decreased vessel size in EV, mDLL4 and mJAG1 
groups (IV-VI versus I-III). Pericyte coverage was also 
significantly increased in DBZ-treated mDLL4 and 
mJAG1 groups (V-VI versus II-III). 
The percentage of pericyte coverage in over-
expressing tumours treated with both DBZ and 
bevacizumab was similar to that in tumours treated with 
DBZ alone (XI-XII versus V-VI).
Notch activation in all these tumours was confirmed 
by verifying the expression of hHEY1 from human tumour 
cells and mHEY1 from mouse stromal cells with QPCR 
(Figure 3D). Higher expression of mHEY1 was detected 
in all tumours compared to hHEY1 expression. DBZ 
inhibited Notch signalling in tumours as shown by down-
regulation of both mHEY1 and hHEY1 in mDLL4- and 
mJAG-tumours. 
DLL4 and JAG1 induced endogenous DLL4 
expression in tumour tissues and vessels
Endogenous DLL4 was abundantly expressed 
in tumour vasculature (Figure 4A I-III) as revealed by 
anti-mouse and human DLL4 antibody staining. DLL4 
expression was also very high in mDLL4-tumours, 
confirming the over-expression in these cells, but also 
in the vessels (II, V, VIII and XI), suggesting a positive 
feedback loop. Expression of endogenous DLL4 in 
the vessels was diminished with DBZ treatment in EV-
tumours and mJAG1-tumours (IV and VI). However 
the reduction of DLL4 expression in vessels was not 
prominent in mDLL4-tumours treated with DBZ, 
bevacizumab or combination (V, VIII and XI), suggesting 
Figure 3: DLL4 and JAG1 mediated tumour resistance to anti-VEGF therapy. A. Tumour growth curves (left panel) and linear 
plot of tumour volume (right panel) of U87-EV and U87-mDLL4 treated with PBS control, DBZ, bevacizumab (mAb), and combination 
of DBZ with bevacizumab. Each group consisted of 5 mice. A generalized linear model with random effects for tumour growth was used to 
analysis growth curves. ANOVA F-test was used to assess significance between curve fits. B. Tumour growth curves (left panel) and linear 
plot of tumour volume (right panel) of U87-EV and U87-mJAG1 treated with PBS control, DBZ, bevacizumab (mAb), and combination 
of DBZ with bevacizumab. Each group consisted of 5 mice. C. Tumour vascular phenotypes revealed by immunofluorescence double 
staining for vessels (CD31, green) and for pericytes (NG2, red) (left panel) as well as quantifications of vessel number, vessel size and 
vessel positive for pericytes (right panels). Immunofluorescent images (magnification 200X) were acquired for five randomly chosen fields 
per tumour section. Each group consisted of 5 tumours. ANOVA with Bonferroni’s post-test.D. Quantification of Notch target expression 
of mHEY1 in tumour stroma (mouse) and hHEY in tumour cells (human) by QPCR. ANOVA with Bonferroni’s post-test. Each group 
consisted of 5 tumours. *P<0.05, ** P<0.01. Each image in left panel or column in right panels represents: I/1, U87-EV control; II/2, U87-
mDLL4 control; III/3, U87-mJAG1 control; IV/4, U87-EV DBZ; V/5, U87-mDLL4 DBZ; VI/6, U87-mJAG1 DBZ; VII/7, U87-EV mAb; 
VIII/8, U87-mDLL4 mAb; IX/9, U87-mJAG1 mAb; X/10, U87-EV DBZ+mAb; XI/11, U87-mDLL4 DBZ+mAb; XII/12, U87-mJAG1 
DBZ+mAb.
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Figure 4: DLL4 and JAG1 induced endogenous DLL4 expression in tumour vessels. A. Expression of DLL4 (red) and 
CD31 (green) as revealed by immunofluorescence double staining of tumour sections of U87. Magnification 200X.B. Endogenous hDLL4 
expression in parental U87 cells (GFP-negative) sorted from co-culture of parental U87, U87-EV, U87-mDLL4 or U87-mJAG1 (GFP-
positive) with an equal amount of parental U87 cells. hDLL4 expression in GFP-negative U87 cells was detected by FACS staining with 
anti-DLL4 antibody (recognised both human and mouse DLL4). ANOVA with Bonferroni’s post-test. NS, no statistical difference. N = 3. 
Error bars represent SD. C. Endogenous hDLL4 expression in parental HMEC-1 cells (GFP-negative) sorted from co-culture of parental 
U87, U87-EV, U87-mDLL4 or U87-mJAG1 (GFP-positive) with an equal amount of parental HMEC-1 cells. hDLL4 expression in GFP-
negative HMEC-1 cells was detected by FACS staining with anti-DLL4 antibody. ANOVA with Bonferroni’s post-test. NS, no statistical 
difference. N = 3, Error bars represent SD. *P<0.05, ** P<0.01, *** P<0.001.
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the enhanced expression of endogenous DLL4 by mDLL4 
was more resistant to reversal by DBZ.
Bevacizumab profoundly pruned the vessels leaving 
behind surviving vessels that expressed high levels of 
DLL4 in all three types of tumours (VII-IX). Increased 
DLL4 expression was observed in EV-tumours treated 
with bevacizumab compared to control (VII versus I) 
as DLL4 is induced by hypoxia through HIF-1α [10]. 
Lesser DLL4 expression was observed in the vasculature 
of mJAG1-tumours compared to mDLL4-tumours when 
treated with bevacizumab (IX versus VIII) as well as 
treated with the combination of DBZ and bevacizumab 
(XII versus XI) but more DLL4 expression occurred in 
the vasculature of mJAG1-tumour than in EV-tumours 
when treated with the combination (XII versus X). DLL4 
stained positively on tumour and/or stromal cells, and 
increased especially in cells surrounding tumour vessels 
when EV-tumours and mJAG1-tumours were treated with 
bevacizumab (VII and IX) as well as treated with the 
combination (X and XII).
To validate the in vivo results, we performed in vitro 
co-culture assays by mixing of an equal amount of over-
expressing cells containing GFP expression encoded by 
the retrovirus vector with parental cells without retrovirus 
transduction (GFP-negative), and detected endogenous 
expression of hDLL4 or hJAG1 in parental (neighbouring) 
cells by FACS staining with anti-DLL4 or JAG1 mAbs 
respectively (Supplementary Figure S3). mDLL4 
expressed in U87 cells (Figure 4B) greatly stimulated 
endogenous hDLL4 expression in neighbouring U87 cells 
compared to either parental basal or EV control (mDLL4 
versus EV or parental). mJAG1 expressed in U87 cells also 
significantly stimulated endogenous hDLL4 expression 
in neighbouring U87 cells compared to both controls 
(mJAG1 versus EV or parental) but substantially weaker 
than mDLL4 did (mJAG1 versus mDLL4). Co-culture of 
mDLL4-expesssing U87 with HMEC-1 cells (Figure 4C) 
demonstrated that mDLL4 expressed in U87 significantly 
induced hDLL4 expression in HMEC-1 cells compared 
to EV control (mDLL4 versus EV). Similarly, mJAG1 
expressed in U87 cells greatly induced hDLL4 expression 
in HMEC-1 cells compared to EV control (mJAG1 versus 
EV) but significantly weaker than mDLL4 did (mJAG1 
versus mDLL4). Mixture of mDLL4-expressing with 
mJAG1-expressing U87 cells induced hDLL4 expression 
in HMEC-1 as did by mDLL4-expressing U87 alone 
(mDLL4+mJAG1 versus mDLL4).
Similar experiments were also performed for SAS, 
PC3 and DU145 tumour cells (Supplementary Figure 
S4). In vivo, both mDLL4 and mJAG1 increased the 
expression of DLL4 in tumour tissues but there was more 
induction by mDLL4 than by mJAG1 (Supplementary 
Figure S4A). In vitro, similar results were obtained from 
the co-culture assays of SAS (Supplementary Figure 
S4B), PC3 (Supplementary Figure S4C) or DU145 cells 
(Supplementary Figure S4D).
DLL4 and JAG1 increased endogenous JAG1 
expression in tumour tissues
Endogenous JAG1 was weakly expressed in the 
vessels (Figure 5A). Notably, expression of endogenous 
JAG1 intensified in tumour and stromal cells of mDLL4-
tumour compared to that of EV-tumour (II versus I). JAG1 
was abundantly expressed in mJAG1-expressing tumours 
ratifying the transduction efficacy (III, VI, IX and XII). 
Inhibition with DBZ resulted in abated JAG1 expression 
in mDLL4-tumours compared to that of mDLL4-tumour 
control (V versus II) while bevacizumab had no significant 
effects on JAG1 expression in all three types of tumours 
compared to that of all control tumours (VII-IX versus 
I-III). Combined treatment with DBZ and bevacizumab 
dramatically reduced expression of endogenous JAG1 in 
both EV- and mDLL4-tumours (X-XI versus I-II).
In vitro co-culture experiments showed that either 
mDLL4 or mJAG1 expressed in U87 cells dramatically 
induced endogenous hJAG1 expression in neighbouring 
U87 cells (Figure 5B) although the intensity was slightly 
higher induced by mJAG1 than by mDLL4 in U87 cell 
(mJAG1 versus mDLL4). Co-culture of over-expressing 
U87 cells with HMEC-1 cells revealed that either mDLL4 
or mJAG1 expressed in U87 cells significantly stimulated 
endogenous hJAG1 expression in HMEC-1 cells compared 
to the EV control (Figure 5C).
Similar experiments were performed for SAS, PC3 
and DU145 tumour cells (Supplementary Figure S5). 
In vivo, both mDLL4 and mJAG1 expressed in tumour 
cells increased endogenous JAG1 expression in tumour 
tissues of either SAS (Supplementary Figure S5A) or 
PC3 (Supplementary Figure S5B). In vitro, similar 
results were obtained from the co-culture assays of SAS 
(Supplementary Figure S5C) and DU145 (Supplementary 
Figure S5D) but the intensity of endogenous hJAG1 
induced by mJAG1 was higher than by mDLL4.
DLL4 rather than JAG1 decreased tumour 
hypoxia
Consistent with our previous work with hDLL4 
[7], mDLL4 significantly diminished CAIX expression 
in mDLL4-tumours compared to that in EV-tumours 
(Figure 6) as revealed by CAIX (brown) (Figure 6A) 
and CD34 (grey) dual staining (Figure 6B) and by its 
quantification (Figure 6C). A weaker CAIX staining was 
observed around bigger and perfused vessels in mDLL4-
tumours (Figure 6B). This effect was reversed when Notch 
signalling was blocked with DBZ treatment rendering the 
tumours more hypoxic in EV and mDLL4 groups (IV-V 
versus I-II). Both groups had an increase in hypoxia with 
either DBZ (IV-V) or bevacizumab treatment (VII-VIII) 
with an additive effect with combination treatment seen in 
mDLL4-tumours (XI). In contrast, expression of mJAG1 
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Figure 5: DLL4 and JAG1 induced endogenous JAG1 expression in tumour tissues. A. Expression of JAG1 (red) and 
CD31 (green) as revealed by immunofluorescence double staining of tumour sections of U87. Magnification 200X. B. Endogenous hJAG1 
expression in parental U87 cells (GFP-negative) sorted from co-culture of parental U87, U87-EV, U87-mDLL4 or U87-mJAG1 (GFP-
positive) with an equal amount of parental U87 cells. hJAG1 expression in GFP-negative U87 cells was detected by FACS staining with 
anti-human JAG1 mAb (64D). ANOVA with Bonferroni’s post-test. N = 3, Error bars represent SD. C. Endogenous hJAG1 expression 
in parental HMEC-1 cells (GFP-negative) sorted from co-culture of parental U87, U87-EV, U87-mDLL4 or U87-mJAG1 (GFP-positive) 
with an equal amount of parental HMEC-1 cells. hJAG1 expression in GFP-negative HMEC-1 cells was detected by FACS staining with 
anti-human JAG1 mAb (64D). ANOVA with Bonferroni’s post-test. NS, no statistical difference. N = 3, Error bars represent SD. *P<0.05, 
** P<0.01, *** P<0.001.
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did not significantly reduce CAIX expression compared to 
EV-tumours (III versus I). Treatment of mJAG1-tumours 
with DBZ (VI) or bevacizumab (IX) did not significantly 
affect the level of CAIX expression compared to control-
treated mJAG1 tumours (III) but the combination 
treatment significantly increased hypoxia (XII versus III).
Both mDLL4 and mJAG1 significantly reduced 
tumour necrosis in either mDLL4- or mJAG1-tumours 
(Figure 6A and 6D) compared to that of EV-tumours (II-
III versus I) while treatment with DBZ obviated the effect 
and increased necrosis (IV-VI versus I-III). Bevacizumab 
treatment increased necrosis in EV-tumours (VII versus 
I) but not in mDLL4- and mJAG1-expressing tumours 
(VIII-IX versus II-III). Combined treatment with DBZ 
and bevacizumab enhanced necrosis in all groups (X-XII 
versus I-III).
Blockade of DLL4 inhibited JAG1-tumour 
growth and increased vessel branching
To further investigate the interplay between JAG1 
and DLL4 in promoting tumour growth, we used specific 
anti-DLL4 mAb (MedImm) that recognises both human 
Figure 6: Immunohistochemical staining for hypoxia and tumour vessels in xenograft tumours. A. Intra-tumour hypoxia 
staining of U87 tumour sections using carbonic anhydrase IX (CAIX) (brown). B. Double staining for CAIX (brown) and blood vessels 
(CD34) (blue) on tumour sections of U87. C. Tumour hypoxia quantification. ANOVA with Bonferroni’s post-test. Each group contained 
5 tumours. D. Tumour necrosis quantification. ANOVA with Bonferroni’s post-test. Each group contained 5 tumours. *P<0.05, ** P<0.01. 
Each image in left panel or column in right panels represents: I/1, U87-EV control; II/2, U87-mDLL4 control; III/3, U87-mJAG1 control; 
IV/4, U87-EV DBZ; V/5, U87-mDLL4 DBZ; VI/6, U87-mJAG1 DBZ; VII/7, U87-EV mAb; VIII/8, U87-mDLL4 mAb; IX/9, U87-
mJAG1 mAb; X/10, U87-EV DBZ+mAb; XI/11, U87-mDLL4 DBZ+mAb; XII/12, U87-mJAG1 DBZ+mAb.
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DLL4 and mouse DLL4 to block DLL4-induced Notch 
signalling in mJAG1-expressing tumours. Blocking 
DLL4-Notch signalling with anti-DLL4 mAb significantly 
delayed tumour growth (Figure 7A) and increased mouse 
survival in both EV- and mJAG1-tumours (Figure 7B). 
Immunohistochemical staining for CD34 (Figure 7C) 
revealed that the treatment with anti-DLL4 mAb strikingly 
increased vessel branching in both EV- and mJAG1-
tumours (Figure 7D), suggesting a predominant role of 
DLL4 in the control of tumour angiogenesis and tumour 
growth in either EV-tumours or mJAG1-tumours.
DISCUSSION
mDLL4-induced Notch signalling appeared to be 
greater than mJAG1-induced signalling. mDLL4 increased 
endogenous DLL4 expression in a feed-forward manner 
[30] while mJAG1 increased DLL4 expression to a lesser 
extent. However, mDLL4 inhibited sprouting while 
mJAG1 induced sprouting angiogenesis. Such opposing 
effects were validated by overexpression and knockdown 
of endogenous ligands. Indeed, increased DLL4 signalling 
has been shown to synchronise fluctuations of DLL4 
expression in individual ECs [25] and to change tip 
cells to stalk cells therefore reducing sprouting [27, 31] 
and driving vessel expansion [25]. JAG1 signalling was 
reported to be weak and antagonise DLL4 signalling, thus 
leading to an increase in tip cell formation and sprouting 
[26]. However, we showed that both DLL4- and JAG1-
Notch signalling are significantly increased by either 
mDLL4 or mJAG1 in vitro.
mDLL4 and mJAG1 reduced cell proliferation in 
vitro but increased tumour growth in vivo as described for 
hDLL4 previously [7], suggesting a key role of tumour 
microenvironment. Indeed, both ligands reduced pericyte 
coverage. This reduction did not lead to a decrease in 
vessel stability. The vessels were in fact better perfused, 
suggesting that enhanced Notch signalling result in 
increased vessel stability either via the ECs themselves 
or via tumour-EC interactions. Recently it was reported 
that tumour cells can differentiate into ECs [32, 33] 
but we have found no such evidence in our xenograft 
models. Crosstalks between Notch and Wnt signalling 
induced by DLL4 [34] and JAG1 [35] have recently been 
shown to play a role in vessel stability. JAG1 has been 
shown to positively regulate vascular smooth muscle cell 
(SMC) coverage in certain models [26, 36, 37]; however 
Notch signalling has been shown to inhibit aortic SMC 
differentiation through an RBP-Jκ/Hey-dependent 
mechanism [38].
Tumour immunostaining revealed different 
vessel phenotypes. mDLL4 decreased vessel number 
but harboured bigger vessels as described previously 
with hDLL4 [6, 7] while JAG1 increased tumour vessel 
numbers only. Both types of vasculature were capable 
of increasing tumour growth via increased perfusion and 
decreased necrosis. Both ligands upregulated mHEY1 
more than hHEY1, implying that paracrine signalling from 
tumour cells to stromal cells is stronger than autocrine 
signalling within tumour cells, supporting a vasculature-
dependent mechanism for the enhanced tumour growth.
The effects of DLL4-Notch signalling on stromal 
cells in tumour microenvironment may be greater than that 
of mJAG1-Notch signalling. Indeed, endogenous DLL4 
expression was higher in tumour vessels, particularly 
in those larger vessels which are known to have greater 
perfusion [7] and more resistant to anti-VEGF therapy [6]. 
Enhanced DLL4 expression by mDLL4 was also found 
in tumour and stromal cells. These stromal cells include 
tumour-associated macrophages [39, 40] which are known 
to accumulate in hypoxic areas in tumours, particularly in 
tumours treated with anti-VEGF therapy [41]. In vitro co-
culture assays supported the findings in vivo. Both mDLL4 
and mJAG1 expressed on different types of tumour cells 
strongly stimulated the expression of endogenous hDLL4 
and hJAG1 in neighbouring cells including tumour cells 
themselves and HMEC-1 cells. Such autocrine and 
paracrine feed-forward signalling were much higher for 
induction of endogenous hDLL4 by mDLL4 than by 
mJAG1 in all types of tumour cells we have examined and 
in HMEC-1 ECs as well. Clearly, no antagonising effects 
between DLL4- and JAG1-Notch signalling were found. 
Both mDLL4 and JAG1 xenografts had an increased 
sensitivity to DBZ compared to EV-tumours, suggesting 
that Notch signalling is responsible for the enhanced 
tumour growth [6]. We have previously demonstrated that 
hDLL4 is responsible for tumour resistance to anti-VEGF 
therapy [2, 6]. Here we found that mDLL4 and mJAG1 
also conferred tumour resistance to bevacizumab in which 
the resistance triggered by mDLL4 was greater than that of 
mJAG1. Combination treatment had a synergistic efficacy 
against mJAG1-tumours as a complete reversal of the 
growth to even below the control level was achieved. It 
was reported that Notch signalling controls macrophage 
recruitment during angiogenesis and DLL4 on ECs 
activates Notch signalling on macrophages [42, 43]. This 
further enhancement by DLL4 may also contribute to its 
superior resistance.
The variation in vasculature phenotypes between 
mDLL4 and mJAG1 tumours may be explained by 
differences in downstream signalling activated by these 
ligands. DLL4 stimulation but not JAG1 was found 
to markedly induce EphrinB2 expression in ECs [44]. 
EphrinB2 is a key player in vessel size in angiogenesis 
[45] and arteriogenesis [46]. In fact, we found previously 
that EphB4-EphrinB2 signalling activated in DLL4-
expressing tumours is, to some extent, responsible for the 
increased vessel size and tumour resistance to anti-VEGF 
therapy [6].
Expression of mJAG1 increased vessel numbers 
in xenograft tumours. Indeed, an increase in sprouting 
angiogenesis has been demonstrated in the retina of mice 
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Figure 7: Anti-DLL4 antibody inhibited in vivo growth of U87-EV and U87-mJAG1 tumours and increased vessel 
branching. A. Tumour growth curves of U87-EV and U87-mJAG1 treated with anti-DLL4 blocking antibody (5mg/kg body weight) or 
PBS control. Each group consisted of 7 mice. Parametric generalized linear model with random effects was used for statistical test. B. Anti-
DLL4 antibody increased tumour-bearing mouse survival. Kaplan-Meier analysis for overall survival test. Each group consisted of 7 mice. 
C. Visualisation of tumour xenograft vasculatures as revealed by CD34 staining. D. Quantification of vessel branching by branching vessel 
index (BVQ). Each group consisted of 7 tumours. Student’s t-test. *P<0.05, ** P<0.01, *** P<0.001. E. A model demonstrating the effects 
of DLL4 or JAG1 on tumour angiogenesis and tumour growth. Angiogenic sprouting is aided by filopodia in response to VEGF gradient. 
DLL4-Notch signalling is promoted in vessels and tumours by increasing downstream gene expression. Signalling from tip cell to stalk 
cell specifies cell fate contributing to tumour growth. DLL4 and JAG1 amply Notch signalling by increasing their expressions. DLL4 is 
downstream of JAG1. JAG1 requires DLL4 for effect rather than antagonising it. The less induction of DLL4 by JAG1 than by DLL4 itself 
may produce less extreme phenotype with an increase in tip cells induced by JAG1 balanced by differentiation of stalk cells, implying a 
model of reciprocal regulation of the two cell populations. Both DLL4 and JAG1 promoted tumour growth but effectively reduced tumour 
necrosis through formation of different vasculature morphology.
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with JAG1 gain-of-function [26] and tumour models 
with such mice [28]. It was suggested that JAG1 is 
antagonising Notch signalling in the stalk cells to reverse 
the reduction in VEGFR2 expression induced by DLL4 
signalling in the retina model [26] and in adult mouse skin 
wound healing [27]. However, this cannot explain the 
phenotypes we observed in our xenografts. Implantation 
of an equal amount of mDLL4- and mJAG1-expressing 
tumour cells in mice did not shown significant growth 
difference among mDLL4-tumour, mJAG1-tumour and 
mDLL4/mJAG1-tumour (see Figure 2C), suggesting 
no such antagonism for tumour growth. Perhaps, 
expression of DLL4 and/or JAG1 in different cell types 
such as ECs, tumour cells or other stromal cells might 
have different effects due to the lateral inhibition [25]. 
Notch signalling is significantly increased by JAG1 in 
vitro and in vivo, especially in tumour stromal cells. In 
addition both mDLL4- and mJAG1-tumours are resistant 
to bevacizumab treatment. If mJAG1 were reversing the 
level of VEGFR2 in tumour vessels a greater response to 
bevacizumab would be expected. However bevacizumab 
only partially reduced tumour growth and was capable of 
decreasing vessel density in both tumours. 
To investigate this further, we treated the mJAG1-
tumours with anti-DLL4 blocking antibody that 
recognises both human DLL4 and mouse DLL4. If 
mJAG1 were antagonising DLL4 signalling, anti-DLL4 
treatment should have a little effect. However, we found 
that anti-DLL4 antibody was still capable of inhibiting 
tumour growth of both EV-tumour and mJAG1-tumour 
significantly. Blocking DLL4 signalling using anti-DLL4 
antibody effectively delayed tumour growth possibly 
by disrupting functional angiogenesis [6-8, 19, 20, 47], 
implying that DLL4 is a dominant ligand over JAG1 in 
tumour angiogenesis and tumour growth. 
In all xenograft models we tested, the same effects 
of mDLL4 and mJAG1 on the vascular phenotype 
were found, that is, mDLL4 reduced vessel numbers 
but increased vessel sizes while mJAG1 only increased 
vessel numbers. However, only in U87 xenograft model 
both mDLL4 and mJAG1 increased the tumour growth. 
In fact, such variability in tumour response to Notch-
regulated angiogenesis has been already noted [7, 8, 19] 
and potentially related to many factors such as changes 
in cancer stem cell phenotype in the tumours [12], 
dependence on vascular co-option versus angiogenesis, 
and different microenvironments between different tumour 
types.
Altogether, we propose a model (Figure 7E) to 
depict the role of DLL4 and JAG1 in tumour angiogenesis 
and growth. JAG1 can enhance angiogenesis not by 
antagonising DLL4 but in a manner that requires DLL4 
induction. JAG1 can induce DLL4 expression but to a 
lesser extent than DLL4 itself. DLL4 decreases vessel 
number but increases vessel size. Both DLL4 and JAG1 
increase vessel perfusion and thus reduce necrosis and 
enhance tumour growth. Our results may have implications 
for development of anti-Notch therapies and suggest that 
anti-JAG1 therapy should be explored in conjunction with 
anti-DLL4 treatment in clinics. 
MATERIALS AND METHODS
Cell culture and reagents
Immortalised human dermal microvascular 
endothelial cells (HMEC-1) were obtained from from 
ATCC through the CDC [48]. Human umbilical vein 
endothelial cells (HUVEC) were isolated from fresh 
umbilical cords [10]. Human cancer cell lines, U87GM 
(U87) glioblastoma cells, SAS head and neck cancer cells, 
PC3 and DU145 prostate cancer cells, were purchased 
from ATCC. Cell line authentication was carried out by 
STR analyses (LGC Standards). Cell lines over-expressing 
empty vector (EV), murine DLL4 (mDLL4) and murine 
JAG1 (mJAG1) were generated by retrovirus transductions 
as described previously [7]. Cultures of the tumour cells 
(U87, SAS and PC3, DU145) and HUVEC cells were 
described previously [7]. HMEC-1 cells were grown in 
MCDB-131 medium supplemented with 10% FCS, 100U/
ml penicillin, 100μg/ml streptomycin, 10mM L-glutamine, 
10ng/ml epidermal growth factor (Sigma), and 1μg/ml 
hydrocortisone (BD Biosciences, Heidelberg, Germany). 
Recombinant human DLL4 (rhDLL4, Catalog no 1506-
D4-050) and rat JAG1 (rrJAG1, Catalog no 599-JG-100) 
were purchased from R&D. Dibenzazepine (DBZ), a 
γ-secretase inhibitor, was purchased from Syncom (The 
Netherlands) at a purity of 99.8% at 232nm. Anti-DLL4 
blocking mAb, a human IgG1 isotype that cross-reacts 
with both human DLL4 and mouse DLL4 (MedImm) was 
supplied as previously [49]. Anti-JAG1 mAbs, clone 65D 
that reacts with human JAG1 only with a high affinity and 
clone 142B that cross-reacts with human and mouse JAG1 
with a low affinity compared to 65D, were made in-house.
In vitro cell proliferation assay
Cells were seeded onto 6-well plates at 0.5-2 x 105 
cells per well (depending on cell lines) and incubated in 
the CO2 incubator at 37
oC. Cells were counted everyday 
over 5-6 days using the Z2 Coulter Counter (Beckman 
Coulter). 
Real-time quantitative PCR (QPCR)
RNA extraction from tumour tissues and QPCR were 
performed as described previously [7]. Primers and probes 
for QPCR were designed using the Probe Library Assay 
Design Centre website (Roche Applied Science, Burgess 
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Hill). Primer sequences and probes are: human GAPDH 
forward primer 5’-AGCCACATCGCTCAGACAC-3’, 
reverse primer 5’-GCCCAATACGACCAAATCC-3’ 
and probe 60; human ACT forward primer 
5’-GAGGAGGCACCGGTAAATG-3’, reverse 
primer 5’-GTCACTCACTGGGACATAGGC-3’ 
and probe 81; human DLL4 forward primer 
5’-CCCTGGCAATGTACTTGTGAT-3’, reverse 
primer 5’-TGGTGGGTGCAGTAGTTGAG-3’ 
and probe 23; human JAG1 forward primer 
5’-GAATGGCAACAAAACTTGCAT-3’, reverse 
primer 5’-AGCCTTGTCGGCAAATAGC-3’ 
and probe 42; human HEY1 forward primer 
5’-CGAGCTGGACGAGCCCAT-3’, reverse 
primer 5’-GGAACCTAGAGCCGAACTCA-3’ 
and probe 39; human HEY2 forward primer 
5’-GTACCATCCAGCAGTGCATC-3’, reverse 
primer 5’-AGAGAATTCAGGGCATTT-3’ 
and probe 60; mouse ACT forward primer 
5’-AAGGCCAACCGTGAAAAGAT-3’, reverse 
primer 5’-GTGGTACGACCAGAGGCATAC-3’ 
and probe 56; mouse HEY1 forward primer 
5’-CATGAAGAGAGCTCACCC-3’, reverse primer 
5’-CGCCGAACTCAAGTTTCC-3’ and probe 17. All 
primers were synthesised by Invitrogen, and probe Library 
was purchased from Roche Applied Science.
Small interfering RNAs
The small interfering RNAs (siRNAs) were designed 
using the siDESIGN Center website (Dharmacon, 
Lafayette, USA) and synthesised by Eurogentec 
(Southampton). siRNA sequences are: scrambled control 
sense 3’-UCUGAAAAGCACGCUUGAC-5’ and 
antisense 3’-GUCAAGCGUGCUUUUCAGA-5’; siDLL4 
Duplex1 sense 3’-CAACUAUGCUUGUGAAUGU-5’ and 
antisense 3’-ACAUUCACAAGCAUAGUUG-5’; siDLL4 
Duplex2 sense 3’-ACACAAACCAGAAGAAGGA-5’ and 
antisense 3’-UCCUUCUUCUGGUUUGUGU-5’; siJAG1 
Duplex1 sense 3’-AUCUUAUGAGGGAUUUACG-5’ and 
antisense 3’-CGUAAAUCCCUCAUAAGAU-5’; siJAG1 
Duplex2 sense 3’-AACAGGACAAACAAACAGG-5’ 
and antisense 3’-CCUGUUUGUUUGUCCUGUU-5’. 
HMEC-1 cells were transfected with siRNA (20nM for 
siDLL4 and 5nM for siJAG1) using HiPerfect (QIAGEN) 
according to manufacturer’s instructions. 
Hanging drop assay
HMEC-1 cells were suspended in medium 
containing 0.2% (w/v) carboxymethylcellulose and 
seeded in non-adherent 60-microwell minitrays (Sigma). 
Spheroids with defined size and cell number (500 cells/
spheroid) were generated overnight. They were then 
embedded into Matrigel in a 24-well plate and allowed to 
polymerize before adding medium. Pictures were taken at 
10× magnifications using an Axiovert 100M microscope 
(Zeiss, Germany). Capillary sprouting was assessed by 
measuring the average length of three longest sprouts 
per spheroid [50] originating from 15 randomly selected 
spheroids per well on day 3 when sprouting was most 
eminent, using Image J. 
Flow cytometry
Cell co-culture of retrovirus transduced tumour 
cells or EC cells, which are expressing GFP protein 
encoded by the retrovirus vector, with an equal amount 
of each parental tumour or EC line (including U87, SAS, 
PC3, DU145 or HMEC-1) (50:50 ratio) were performed 
in 6-well plates or 10-cm cell culture dishes in the CO2 
incubator at 37oC for 2-3 days until the confluence of 
cell growth. The cells were then harvested for FACS 
staining by incubating with a primary antibody at 40C for 
30 minutes. Primary antibodies used include MedImm 
human anti-DLL4 blocking mAb (which cross-reacts 
with both human DLL4 and mouse DLL4) and in-house 
made mouse anti-JAG1 mAbs (clone 65D reacts with 
human JAG1 only with a high affinity while clone 142B 
cross-reacts with human JAG1 and mouse JAG1 with a 
low affinity compared to 65D). After washed with PBS 
for 3 times each 3-5 minutes, the cells were incubated 
with PE- or APC-conjugated secondary antibodies at 40C 
for 30 minutes. After washed with PBS, the cells were 
sorted for GFP-negative and GFP-positive portions on the 
BD Fortessa X-20 FACS machine and analysed for the 
expression of DLL4 and JAG1 with the FlowJo software. 
Xenograft mouse models
Animal experiments were performed as previously 
described [7] under Home Office legislation. DBZ (8.1 
µmol/kg of body weight) and bevacizumab (10mg/kg of 
body weight) were given intraperitoneally every three 
days, starting when the tumour reached 150mm3 in size 
[6]. MedImm anti-DLL4 blocking mAb (5 mg/kg body 
weight) was administered twice a week starting when 
EV-control tumour reached 150mm3 in size. Mice were 
sacrificed when reach to the criteria defined in the animal 
project license.
Immunostaining
The mouse CD31 and NG2 staining protocol on 
frozen sections and quantification were performed as 
described previously [7]. For the xenografts treated with 
anti-DLL4 antibody A visual vessel scoring method was 
employed to determine the number of branched vessels 
(BVQ). A score of 0-5 was given by two independent 
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observers for vessel scoring. Biotinylated Lycopersicon 
Esculentum (tomato) lectin (1µg/µl) was injected 
intravenously into tail vein 10 min prior to euthanasia to 
determine vessel perfusion [7]. Images were taken from 
the most vascularised areas to determine percentage of 
perfusion in existing vessels. Percentage of perfusion 
was calculated as the percentage area positive for tomato 
lectin compared to the CD31 positive area. DLL4 and 
JAG1 expression was detected with anti-DLL4 antibody 
(1:100, Abcam) and anti-JAG1 antibody 28H8 (1:100, 
Cell Signalling). For immunofluorescent staining, Alexa-
Fluor 546 donkey anti-goat (0.5 μg/mL, Molecular Probe, 
Invitrogen) and Alexa-Fluor 488 donkey anti-rabbit (0.5 
μg/mL, Molecular Probe, Invitrogen) secondary antibodies 
were used. Samples were sequentially scanned with a 
Zeiss LSM 510 Meta 63X objective (Plan-achromat 63X 
11.40 oil immersion). CAIX staining was detected using 
CAIX M75 antibody at 1:50 as described previously [7]. 
Necrosis was quantified histologically on hematoxylin-
stained sections [6]. 
Statistical analysis
Prism software was used to analyse the data. The 
nalysis of variance (ANOVA) test was used to compare 
mean values among three or more data sets, and the 
Bonferroni’s post-test to compare any two data sets among 
the three or more sets. Non-parametric Kruskal-Wallis test 
with Dunn’s post-test comparison was also employed. A 
generalized linear model with random effects for tumour 
growth was used to analysis growth curves. ANOVA 
F-test was used to assess significance between curve fits. 
Kaplan-Meier survival curves were used to analyse the 
percentage survival of mice. All data were presented as 
Mean±SEM except when indicated specifically in figure 
legends. Statistical significance was indicated in figures 
with an asterisk where P < 0.05, two asterisks where P < 
0.01 and three asterisks where P < 0.001.
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Supplementary Figure 1. DLL4 and JAG1 activated Notch signalling and affected sprouting angiogenesis in vitro.
A) DLL4 activated Notch signalling stronger than JAG1 in primary HUVEC cells. Expression profile of Notch target genes 
in HUVEC cells stimulated with 18nM rhDLL4 or rrJAG1 coated on the plate over a time course. QPCR was used to determine mRNA 
levels of DLL4, JAG1, HEY1 and HEY2. Fold changes were obtained by normalizing against the EV control. Student’s t-test.
B) Upregulation of mDLL4 and mJAG1 in HMEC-1 cells by retrovirus transductions. Western blotting confirmed the 
expression of mDLL4 and mJAG1. GFP encoded by the retrovirus vector was served as an internal control for the retrovirus transduction 
efficacy. β-actin served as a protein loading control.
C) Knockdown of endogenous hDLL4 in HMEC-1 cells by siRNAs. QPCR confirmed the knockdown of hDLL4 expression at 
the mRNA level (a) by two different siRNA duplexes (20nM), compared to scrambled (Scr) control. Time course expression of hDLL4 at 
the mRNA level (b) and at the protein level confirmed by Western blotting (c) and immunofluorescence staining (d). Representative figures 
were shown (n=2 independent experiments). ANOVA with Bonferroni’s post-test.
D) Knockdown of endogenous hJAG1 in HMEC-1 cells by siRNAs. QPCR confirmed the knockdown of hJAG1 expression at 
the mRNA level (a) by two different siRNA duplexes (20nM), compared to scrambled (Scr) control. Time course expression of hJAG1 at 
the mRNA level (b) and at the protein level confirmed by Western blotting (c) and immunofluorescence staining (d). Representative figures 
were shown (n=2 independent experiments). ANOVA with Bonferroni’s post-test.
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Supplementary Figure 2. Effects of mDLL4 and mJAG1 on cell growth in vitro and tumour growth in vivo of three tumour cell lines 
and on their tumour vasculature
A) FACS staining confirmed the over-expression of mDLL4 and mJAG1 in SAS, PC3 and DU145 tumour cells 
compared to its EV control, respectively.
B) Effects of mDLL4 and mJAG1 expressed in tumour cells on cell growth in vitro. Representative figures were shown (3 
independent experiments). Error bars represent SD.
C) Effects of mDLL4 and mJAG1 expressed in tumour cells on xengoraft growth or mouse overall survival in vivo.
D) Effects of mDLL4 and mJAG1 expressed in tumour cells on their vascular phenotypes.  Immunofluorescence triple 
staining for cell nuclei with DAPI (blue), tumour vessels with anti-CD31 antibody (green) and JAG1 expression with anti-JAG1 antibody 
(red) and quantifications of vessel number and vessel size were performed on tumour sections of SAS cells. Each group consisted of 7 
tumours. ANOVA with Bonferroni’s post-test.
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Supplementary Figure 3. FACS analysis strategy for detection of endogenous hDLL4 and hJAG1 expression in four tumour cell lines 
and HMEC-1 cells.
A) FACS analysis for detection of endogenous ligand expression. Co-culture of parental U87, U87-EV, U87-mDLL4, U87-
mJAG1 or mixture of U87-mDLL4 and U87-mJAG1 cells (containing GFP encoded by the retrovirus vector) with an equal numbers of 
parental U87 cells (GFP-negative) (50:50 ratio) in 6-well plates for 3 days, FACS staining for DLL4 and JAG1 with specific antibodies, 
and then separation of GFP-positive and GFP-negative cells on the BD Fortessa X-20 FACS machine. The expression of DLL4 or JAG1 in 
GFP-positive cells and GFP-negative cells were then analysed with the FlowJo software. 
B) FACS analysis for the expression of DLL4 or JAG1 in GFP-positive U87 cells with MedImm human anti-DLL4 
blocking mAb that cross-reacts with both human and mouse DLL4 and with 65D mouse anti-human JAG1 mAb. 
C) FACS analysis for the expression of DLL4 or JAG1 in GFP-negative U87 cells with MedImm human anti-DLL4 
blocking mAb and with 65D mouse anti-human JAG1 mAb.
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Supplementary Figure 4. DLL4 and JAG1 induced endogenous DLL4 expression in tumour tissues and tumour cells
A) Immunofluorescence triple staining for cell nuclei with DAPI (blue), tumour vessels with anti-CD31 antibody 
(green) and DLL4 expression with Santa Cruz anti-DLL4 antibody C-20 (red) on tumour sections of SAS-EV, SAS-
mDLL4, SAS-mJAG1, and mDLL4+mJAG1-tumours.
B) Endogenous hDLL4 expression in parental SAS cells (GFP-negative) sorted from co-culture of parental SAS, 
SAS-EV, SAS-mDLL4 or SAS-mJAG1 (GFP-positive) with an equal amount of parental SAS cells detected by FACS 
staining with MedImm anti-DLL4 blocking mAb (that recognises both human DLL4 and mouse DLL4). ANOVA with 
Bonferroni’s post-test. N=3. NS, no statistical difference. Error bars represent SD. 
C) Endogenous hDLL4 expression in parental PC3 cells (GFP-negative) sorted from co-culture of parental PC3, 
PC3-EV, PC3-mDLL4 or PC3-mJAG1 (GFP-positive) with an equal amount of parental PC3 cells detected by FACS 
staining with MedImm anti-DLL4 blocking mAb (that recognises both human DLL4 and mouse DLL4). ANOVA with 
Bonferroni’s post-test. N=3. NS, no statistical difference. Error bars represent SD. 
D) Endogenous hDLL4 expression in parental DU145 cells (GFP-negative) sorted from co-culture of parental DU145, 
DU145-EV, DU145-mDLL4 or DU145-mJAG1 (GFP-positive) with an equal amount of parental DU145 cells detected 
by FACS staining with MedImm anti-DLL4 blocking mAb (that recognises both human DLL4 and mouse DLL4). 
ANOVA with Bonferroni’s post-test. N=3. NS, no statistical difference. Error bars represent SD. 
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Supplementary Figure 5. DLL4 and JAG1 induced endogenous JAG1 expression in tumour tissues and tumour cells
A) Immunofluorescence triple staining for cell nuclei with DAPI (blue), tumour vessels with anti-CD31 antibody 
(green) and JAG1 expression with Cell Signalling anti-JAG1 antibody 28H8 (red) on tumour sections of SAS-EV, SAS-
mDLL4, SAS-mJAG1 and SAS-mDLL4+mJAG1 tumours.
B) Immunofluorescence triple staining for cell nuclei with DAPI (blue), tumour vessels with anti-CD31 antibody 
(green) and JAG1 expression with Cell Signalling anti-JAG1 antibody 28H8 (red) on tumour sections of PC3-EV, PC3-
mDLL4, PC3-mJAG1 and PC3-mDLL4+mJAG1 tumours.
C) Endogenous hJAG1 expression in SAS cells (GFP-positive) sorted from co-culture of SAS-EV, SAS-mDLL4 or 
SAS-mJAG1 (GFP-positive) with an equal amount of parental SAS cells  (GFP-negative) detected by FACS staining 
with 65D anti-hJAG1 mAb. ANOVA with Bonferroni’s post-test. N=3. Error bars represent SD. 
D) Endogenous hJAG1 expression in parental DU145 cells (GFP-negative) sorted from co-culture of parental DU145, 
DU145-EV, DU145-mDLL4 or DU145-mJAG1 (GFP-positive) with an equal amount of parental DU145 cells detected 
by FACS staining with 65D anti-hJAG1 mAb. ANOVA with Bonferroni’s post-test. N=3. NS, no statistical difference. Error bars 
represent SD. 
